Editing Tacrine (section)

==Clinical use==
Tacrine was the prototypical [[cholinesterase inhibitor]] for the treatment of [[Alzheimer's disease]]. [[William K. Summers]] received a patent for this use in 1989.<ref>{{cite patent | country = US | number = 4816456 | inventor = Summers WK | gdate = 28 March 1989| title = Administration of monoamine acridines in cholinergic neuronal deficit states}}</ref><ref>{{cite report | vauthors = Waldholz M | title = A Psychiatrist's work leads to a US study of Alzheimer's drug: but Dr. Summers shuns test, seeks to widen his own; is Memory really aided; Fee-for research Furor | work = Wall Street Journal | date =  4 August 1987 | page = A-1 }}</ref><ref>{{cite web | vauthors = Peacock D | title = New Mexico Doctor invents drugs, supplements for Alzheimer's disease, Multiple Sclerosis. | work = NM Bus Weekly | date = 25 March 2005 | url = https://www.bizjournals.com/albuquerque/stories/2005/03/28/smallb2.html }}</ref>  Studies found that it may have a small beneficial effect on cognition and other clinical measures, though study data was limited and the clinical relevance of these findings was unclear.<ref name="Qizilbash1998">{{cite journal | vauthors = Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M | title = Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration | journal = JAMA | volume = 280 | issue = 20 | pages = 1777–1782 | date = November 1998 | pmid = 9842955 | doi = 10.1001/jama.280.20.1777 }}</ref><ref name="Rang2003">{{cite book |vauthors=Rang HP, Dale MM, Ritter JM, Moore PK |title=Pharmacology |edition=5th |location=Edinburgh |publisher=Churchill Livingstone |year=2003|isbn=978-0-443-07145-4}}.</ref>

Tacrine has been discontinued in the [[United States of America|US]]<ref name=MSR>{{cite web |title=tacrine (Discontinued) - Cognex |url= http://reference.medscape.com/drug/tacrine-343070 |work=Medscape Reference|publisher=WebMD|access-date=8 October 2013|archive-date=30 June 2019|archive-url=https://web.archive.org/web/20190630162718/https://reference.medscape.com/drug/tacrine-343070|url-status=dead}}</ref> in 2013, due to concerns over safety.<ref>{{cite web | url = http://www.livertox.nih.gov/Tacrine.htm | title = Tacrine | work = LiverTox | publisher = U.S. National Institutes of Health | archive-url = https://web.archive.org/web/20190702153735/http://www.livertox.nih.gov/Tacrine.htm | archive-date = 2019-07-02 }}</ref>

Tacrine was also described as an [[analeptic]] agent used to promote mental alertness.<ref name="ElksGanellin1990">{{cite book| veditors = Elks J, Ganellin CR |title=Dictionary of Drugs|year=1990|doi=10.1007/978-1-4757-2085-3|isbn=978-1-4757-2087-7}}</ref>